26801-18-3

Upstream product

• 26801-34-3 3-(3,4-dimethylphenyl)-2-propyne-1-ol 

Downstream Products

• 19938-01-3 3-(3,4-dimethylphenyl)propionaldehyde 
• 26801-19-4 1-bromo-3-(3,4-dimethylphenyl)propane 

Relevant academic research and scientific papers

AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF

Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof. wherein each symbol is as defined in the specification.

5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES

The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I),wherein X represents CH2 or O; R1 represents a phenyl group, which group is independently mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, cyano, trifluoromethoxy and trifluoromethyl; R2 represents (C1-4)alkyl, (C1-4)alkoxy, (C2-4)alkenyl, halogen, cyano, hydroxymethyl, trifluoromethyl, C(O)NR5R6 or cyclopropyl; R3 represents (C1-4)alkyl, (C1-4)alkoxy-methyl or halogen; R4 represents (C1-4)alkyl; R5 represents hydrogen or (C1-4)alkyl; and R6 represents hydrogen or (C1-4)alkyl. The invention also relates to pharmaceutically acceptable salts of such compounds; and to the use of such compounds as medicaments; especially as orexin receptor antagonists.

SUBSTITUTED PROPIONYL DERIVATIVES

The present invention relates to a compound represented by the following formula (1): [wherein, X1represents a carboxyl group which may be esterified or the like group; Y1represents a single bond, -O- or -N(R1)-; at least one of A1, A2and A3is a group represented by the following formula (2): -R2-a1-R3-a2→{wherein, R2represents a divalent C2-12hydrocarbon group, R3represents a single bond or a divalent C1-12hydrocarbon group, a1and a2individually represent a single bond, -S-, -SO-, -SO2-, -SO2NH-, -O-, -N(R4)-, -CON(R5)-, -C(=O)- or - Si(R6)(R7)- and → means bonding with Q1, Q2or Q3}, the remaining one or two of A1, A2and A3are the same or different and each independently represents a group represented by the following formula (3): -R8-a3-R9-a4→{wherein, R8and R9individually represent a single bond or a divalent C1-12hydrocarbon group, a3and a4individually represent a single bond, -S-, -SO-, -SO2-, -SO2NH-, -O-, - N(R10)-, -CON(R11)-, -C(=O)- or -SI(R12)(R13)- and → means bonding with Q1, Q2or Q3},; at least one of Q1, Q2and Q3represents a cyclic hydrocarbon group or heterocyclic group and the remaining one or two of Q1, Q2and Q3individually represent a hydrogen atom, a carboxyl group which may be esterified, a hydrocarbon group or a heterocyclic group] or salt thereof; and a pharmaceutical comprising the same as an effective ingredient. The compound exhibits strong squalene synthetase inhibitory action and is therefore useful as a pharmaceutical for the treatment·prevention of hypercholesterolemia, hyperlipemia or arteriosclerosis.